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Summary: Genetic engineering of cell transplant populations offers potential for delivery of 
neurotherapeutic factors to modify the regenerative microenvironment of the injured spinal 
cord. The use of magnetic nanoparticle (MNP) based vectors has reduced the traditional 
reliance on viral methods and their associated obstacles in terms of scale up and safety. Studies 
utilising magnetic assistive platforms for MNP-mediated gene delivery have found transfection 
efficiency in astrocytes (a major transplant and homeostatic neural cell type) to be both 
frequency and amplitude-dependent. It is widely assumed that increased intracellular particle 
load will enhance transfection efficiency in a cell population. Therefore, we tested repeat 
delivery of MNP:plasmid complexes in conjunction with oscillating magnetic field parameters- 
a process termed ‘magneto-multifection’- in astrocytes of primary origin in an attempt to 
enhance transfection levels. We show i) levels of transfection using magneto-multifection 
equal that seen with viral methods; ii) reporter protein expression using two reporter plasmids 
shows a diverse profile of single/dual transfected cells with implications for delivery of a 
‘cocktail’ of neurotherapeutic proteins and, iii) contrary to expectation, an inverse relationship 
exists between particle load and reporter protein expression. 
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Introduction 
Astrocytes have major roles in the normal homeostatic functions of the central nervous system. 
While their roles in neural injury are controversial, several studies suggest that they offer 
promise as a cell transplant population for regenerative treatment of spinal cord injury, being 
of neural origin and with a key role in supporting neuronal survival (Haas & Fischer, 2013). 
Astrocytes also have effective cellular secretory processes meaning that genetically engineered 
astrocytes can play a key role as cellular delivery vehicles for gene transfer in ‘combinatorial’ 
interventions for spinal cord injury and, as such, have been effectively engineered to release 
neurotherapeutic proteins such as NGF and BDNF (Merienne, Le Douce, Faivre, Deglon & 
Bonvento, 2013). However, such studies have usually relied on viral vectors for genetic 
modification which, while they report high transfection efficiencies, can present significant 
challenges for human translational applications, in terms of scale-up and safety. 
In this regard, MNPs have been proven to be highly promising gene delivery agents for genetic 
modification of several major neural transplant populations, offering a number of advantages 
over other transfection techniques (Karra & Dahm, 2010; Laurentt, Sapet, Le Gourrierec, 
Bertosio & Zelphati, 2011). The low transfection efficiency associated with MNP transfection 
has been addressed by deploying oscillating magnetic fields in conjunction with MNPs, 
proving highly advantageous in improving cellular transfection levels (McBain et al., 2008). 
Studies investigating the optimisation of magnetic field oscillation parameters for gene transfer 
to astrocytes have shown that transfection levels are optimal at a frequency of 1 Hz (Pickard & 
Chari, 2010). Additionally, the amplitude of field oscillation plays a role in influencing the 
extent of protein expression in individual cells (Tickle, Jenkins, Polyak, Pickard & Chari, 
2016). A third parameter shown to further enhance MNP-mediated gene delivery is repeat 
administration of MNP:plasmid complexes (termed “multifection”). This approach can not 
only be used to increase the delivery of a single transgene to transplant populations, but also 
the use of different plasmids to enable release of a ‘cocktail’ of therapeutic molecules. 
Additionally, the combined use of multifection and applied magnetic field [termed ‘magneto-
multifection’ (M-Mfect)] has shown significantly increased transfection efficiency in cell 
transplant populations (Pickard, Barraud & Chari, 2011). Therefore, we can predict that 
employing the optimal frequency and amplitude for astrocytes, M-Mfect may enhance 
transfection efficiency and/or the extent of transgene expression in astrocytes; however, this 
has not been tested previously. 
A further important, but often overlooked consideration in transfection studies utilising MNPs 
is the correlation between the extent of nanoparticle uptake and gene expression. While many 
studies have focused on enhancing nanoparticle delivery to cells, no study has, so far, explored 
the relationship between particle load and transgene expression in neural transplant cells. To 
address these issues, we have utilised astrocytes of primary origin to (i) evaluate the efficacy 
and safety of M-Mfect for dual reporter plasmid delivery to astrocytes and, (ii) investigated the 
relationship between cellular nanoparticle load and transfection; both in terms of proportions 
of transfected astrocytes and extent of reporter protein expression per cell. 
Materials & Methods 
The care and use of animals was in accordance with the Animals (Scientific Procedures) Act 
of 1986 (UK), and approved by local ethics committee. 
Following published protocols, MNP-mediated gene [red & green fluorescent protein (RFP; 
GFP)] transfer protocols were conducted at 24-48 h post-plating of primary rodent astrocytes 
(passage 2). The magnefect-nano device [42Bio, LLC (Gainesville, Florida, USA)] offers 
lateral oscillation capabilities with programmable amplitude and frequency. Transfection-
grade MNPs were obtained from OZ Biosciences; commercial forms (NeuroMag) and custom-
synthesized forms (NeuroMag-Fluo; NeuroMag conjugated to rhodamine fluorophore). Briefly, 
following addition of the MNP:plasmid complex, cells were exposed to the optimal magnetic 
field reported for astrocytes (f = 1Hz; 200 µm; 30 min);  incubated in the absence of a magnetic 
field for 30 min, followed by 100% D10 refresh to remove any non-internalised particles (see 
Tickle, Jenkins, Pickard & Chari, 2015). Following a further 7 h incubation, cells were subject 
to a repeat gene transfer protocol. Single transfection acted as controls [Time1 (T1); Time2 
(T2)] for the M-Mfect condition. RFP results in lower transfection efficiency than that seen 
with GFP due to the larger plasmid size of the former - 4.6 kb vs. 3.5 kb (Pickard, Adams, 
Barraud & Chari, 2015); therefore, experiments were duplicated using RFP at T1/GFP at T2 
and GFP at T1/RFP at T2 (n=2; duplicates of each culture). This also enabled evaluation of 
RFP/GFP co-expression. Experiments were terminated 48 h following final MNP:plasmid 
administration. Control wells consisted of cells not exposed to MNP:plasmid complex. Safety 
of the M-Mfect protocol was of prime concern therefore, alongside an MTS assay as an 
indicator of metabolic activity (VICTOR2 Multi-label Counter, PerkinElmer), assessment of 
cell viability was quantified through culture characterisation i.e. average cell count; culture 
purity and prevalence of pyknosis [see published protocols (Tickle, Jenkins, Pickard & Chari, 
2016)]. 
To explore the dose relationship between MNP load and transgene expression, a subset of 
experiments was conducted using NeuroMag-Fluo. The extent of NeuroMag-Fluo cellular uptake 
was based on a previously described semi-quantitative method of low, medium or high particle 
accumulation within the cell (Jenkins, Pickard, Furness, Yiu & Chari, 2013). Fluorescence 
intensity was used as a representative measure of GFP expression. Briefly, fluorescence 
micrographs were converted to grayscale; inverted and calibrated using an optical density step 
tablet, with individual cells then delineated to assess fluorescence intensity. Readings taken to 
correct for background fluorescence were subtracted from the fluorescence intensity cellular 
readings, the resulting value representing the measure of GFP expression in a transfected cell 
(ImageJ software). Particle accumulation vs. GFP expression was compared to allow for 
evaluation of a MNP/GFP dose-relationship. 
Results 
For M-Mfect, plasmids encoding RFP and GFP were used to evaluate transfection efficiency 
at the two time points (Fig. 1a) and to investigate the level of reporter protein co-expression in 
single cells (Fig. 1b). Repeat administration significantly increased overall cellular transfection 
efficiency compared with single MNP:plasmid dose at T1 or T2 alone [81.5 ± 1.9% (M-Mfect) 
vs. 37.9 ± 8.8% (T1) and vs. 43.7 ± 8.1% (T2); **p < 0.01; *p < 0.05 respectively] (Fig. 1c). 
Repeat exposure to MNP:plasmid complexes revealed that only ca. 22% of cells showed co-
expression of RFP/GFP [Fig. 1b-image (+ inset) & Fig 1d]; with the majority of transfected 
cells exhibiting GFP expression (ca. 54%) (Fig. 1d). 
Transfected cells are nanoparticle-loaded cells which, following intranuclear plasmid-DNA 
(pDNA) delivery, subsequently exhibit reporter protein expression. Of the cells here, 
approximately 80% of astrocytes exhibited NeuroMag-Fluo labeling, of which ca. 50% exhibited 
reporter protein expression (Fig. 1e). Labeled cells showed low, moderate or high levels of 
particle accumulation as measured by a visual semi-quantitative analysis (Fig. 1f).  Observation 
of levels of particle accumulation and transgene expression revealed an inverse relationship 
(Fig. 1g). High transgene expression was generally associated with low levels of particle 
accumulation, whereas cells that were highly labeled exhibited a low extent of transgene 
expression. In this regard, although low particle accumulation was always associated with 
reporter protein expression, the observed relationship between higher levels of particle 
accumulation and GFP expression was inconsistent. Higher levels of accumulation were 
observed in association with high, moderate, low or no GFP expression (Fig. 1h). 
The percentage of cells expressing GFAP was consistent across all conditions (98.1 ± 0.5%) 
(Fig. 2a), with no difference found in average cell number (Fig. 2b). Type 1 astrocytes 
accounted for ca. 92% of the GFAP+ve population vs. Type 2 which accounted for ca. 8% 
(Fig. 2c). The Type 1 phenotype made up the majority of transfected cells (ca. 89% vs. Type 
2; ca. 11%) (Fig. 2d). Low levels of pyknosis were observed across all conditions (ca. 3% 
overall) (Fig. 2e), with no difference found in metabolic activity between cells exposed to 
plasmid only or MNP:plasmid complex across each of the experimental conditions (Fig. 2f). 
Discussion 
MNP-mediated gene transfer to astrocytes has previously achieved 60% transfection efficiency 
(Pickard & Chari, 2010). We show here that employing a M-Mfect strategy, utilising the 
optimal parameters for this particular neural cell type, significantly enhanced transfection 
efficiency versus our previous study (> 80% vs. 60%), and was associated with a high degree 
of cell viability. A wider population of the target cells are transfected, with a subpopulation 
showing dual protein expression indicative of repeat MNP:plasmid uptake. Previous studies 
(Pickard & Chari, 2010) have observed rapid intranuclear delivery and transgene expression in 
a subpopulation of astrocytes in as little as 4 h. Potentially, levels of GFP/dual protein 
expression could be significantly enhanced in this same subpopulation, as repeat administration 
of MNP:plasmid complex at 8 h intervals could increase the likelihood of pDNA exposure to 
i) a greater proportion of target cells of which ii) a subpopulation have the potential for dual
protein expression. This has implications for therapeutic gene delivery. A subpopulation of 
cells exhibiting high levels of gene expression could be more beneficial for slow release 
applications due to the transient nature of nucleic acid, and transgene dilution through 
proliferative processes. Conversely, a population containing a large proportion of low 
transgene-expressing cells could be advantageous for immediate ‘one-step’ release of a drug 
or growth protein. Our results on dual-transfected cells suggest however, that only a small 
number (ca. 22%) have the potential to release a ‘cocktail’ of proteins.  
In respect of transfection efficiency, a widely accepted view is that transfection levels will 
directly correlate with nanoparticle load (i.e. Laurentt, Sapet, Le Gourrierec, Bertosio & 
Zelphati, 2011; McBain et al., 2008). Our results question this assumption. Nanoparticle uptake 
is dependent on a number of factors including endocytotic activity of the target cell (Treuel et 
al, 2015). Astrocytes possess a highly endocytotic membrane showing avid MNP uptake 
(Jenkins, Pickard, Furness, Yiu & Chari, 2013; Tickle, Jenkins, Pickard & Chari, 2015; Tickle, 
Jenkins, Polyak, Pickard & Chari, 2016). However, of the ca. 80% labeled cells in this present 
study, only ca. 50% were transfected. Morphological analyses revealed low intracellular 
particle load was associated with high protein expression. Highly labeled cells, for the most 
part exhibited low/no protein expression. These findings indicate an inverse relationship 
between particle load and gene transfer, suggesting high particle uptake is not a major 
determinant of successful transfection.  
For non-viral gene delivery, heterogeneity between particle uptake and gene expression 
appears to be commonplace (Akita, Ito, Kamiya, Kogure & Harashima, 2007). A plausible 
explanation in relation to gene transfer could be cell cycle dynamics which reports a trafficking 
of the various elements – particle and pDNA - throughout the duration of the cell cycle. 
However, it has also clearly identified optimal timings -‘hot spots’- at different stages of the 
cell-cycle for uptake, delivery and subsequent protein expression. The cell cycle of astrocytes 
in culture is ca. 14-20 h, with an M-phase of 2-3 h and an S-phase of ca. 7–10 h.  Particle 
uptake as a delivery vector for pDNA is greatest during the G2/M-phase, with intranuclear 
pDNA delivery comparable throughout the cell cycle, reporting higher levels of uptake during 
mitosis. Subsequent transgene expression is understood to be dependent on mitotic events 
although, significant increases are also reported prior to mitosis (Akita, Ito, Kamiya, Kogure 
& Harashima, 2007; Tseng, Haselton & Giorgio, 1999). 
In this context, particle uptake and subsequent intracellular processing are not continuous but 
rather, a multi-stage process (Pollard et al., 1998). This implies a longer time-course than 
previously supposed, and that the occurrence of one event does not necessarily predict the 
occurrence of a subsequent event.  High cellular particle loading may result in a longer 
trafficking time or be ‘held’ at one stage of the process, potentially impairing DNA release 
from the particle; a possible explanation for the inconsistency observed in highly labeled cells. 
Of importance, contrary to the belief that increased nanoparticle labeling is a precursor to 
enhanced protein expression, the findings from this study would suggest that optimal 
transgene expression, at least in respect of astrocytes, may be due to lower particle uptake 
per cell and in turn, more efficient intracellular processing. 
For the proportion of cells showing dual protein expression, co-expression may be contingent 
on optimal particle loading at each time-point, or/and pDNA release at different time-points 
due to plasmid size. In this regard, electron microscopy in conjunction with cell cycle 
synchronisation would offer insight into the intracellular processing of the MNP:plasmid in 
this neural cell. Further work is needed to establish the mechanisms underlying the reasons for 
the division of a cell population into transfected/non-transfected cells and their capacity for 
dual protein expression. 
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Figure 1. Magneto-multifection and transgene expression. For the M-Mfect experiments, 
transfection efficiency was determined as the percentage of GFAP+ve cells exhibiting 
reporter protein expression (RFP or GFP). Co-expressing (RFP + GFP) cells were confirmed 
by coincident expression of red or green fluorescent protein on unmerged images, with the 
merged image exhibiting a combination of both proteins. Representative fluorescence 
micrographs illustrating (a) two different sub-populations of cells are transfected at T1 and 
T2; characterised respectively by RFP and GFP expression [arrowheads; main image 
(corresponding un-merged images showing RFP and GFP expressing cells)]; (b) The 
prevalence of a subpopulation of cells co-expressing RFP/GFP expression, indicating repeat 
uptake of MNP:plasmid complex [white arrows; main image (corresponding un-merged 
images showing coincident RFP/GFP expression)]. Bar graphs showing (c) repeat 
administration of MNP:plasmid complex significantly increased transfection efficiency 
compared with a single dose at T1 or T2 (**p < 0.01; *p < 0.05 respectively), and (d) a 
greater number of transfected cells exhibit GFP expression vs. RFP, with a subpopulation of 
cells exhibiting RFP/GFP co-expression (n = 3).  Bar graphs show (e) a discrepancy between 
proportions of labeled cells and cells exhibiting GFP expression, with (f) transfected cells 
predominantly showing low levels of particle accumulation. Bar graph (g) shows an inverse 
relationship exists between particle accumulation and levels of GFP expression. Fluorescence 
micrograph (h) shows (i) high levels of GFP expression (white arrow head) in cells exhibiting 
low levels of particle uptake; (ii) extensive particle uptake coupled with negligible GFP 
expression (red arrow) and conversely, medium levels of GFP expression (white arrow) (n = 
2). Scale of main image = 50 µm. Results expressed as mean ± s.e.m. (c; d). GFAP: glial 
fibrillary acidic protein; GFP: green fluorescent protein; MNP: magnetic nanoparticle; RFP: 
red fluorescent protein; T1; T2: Time 1; Time 2 
Figure 2. Safety assessment of M-Mfect protocols. Bar graphs showing (a) the percentage 
of GFAP+ve cells was consistent across all conditions with (b) no difference in average cell 
count. Bar graphs showing (c) proportion of astrocyte phenotype was predominantly Type 1 
(ca. 92% vs. ca. 8% Type 2) with (d) Type 1 phenotype accounting for 89% of transfected 
cells vs. 11% Type 2 phenotype. Bar graphs showing (e) low levels of pyknosis across all 
conditions (ca. 3%) with (f) no difference seen in comparative metabolic activity in each 
condition. (n = 3). Results expressed as mean ± s.e.m. 
